- Durvalumab Plus BCG Reduces High-Risk NMIBC Recurrence or Death Risk by 32% in Phase 3 POTOMAC TrialDurvalumab plus BCG induction and maintenance yielded an HR of 0.68 vs BCG alone for DFS in BCG-naive, high-risk non–muscle-invasive bladder cancer.onclive · 2mo ago↗ source
- Darolutamide Plus ADT Yields Significant OS Benefit in mHSPCDarolutamide plus ADT demonstrated a 50% reduction in the risk of death in metastatic hormone-sensitive prostate cancer.onclive · 2mo ago↗ source
- OncLive Weekly News Quiz (5/15/2026): Did You Catch 3 New FDA Oncology Approvals?Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.onclive · 2mo ago↗ source